




RealRate

PHARMACEUTICAL 2022

Oncotelic Therapeutics Inc
Rank 369 of 471



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Oncotelic Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Oncotelic Therapeutics Inc compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 135% points. The greatest weakness of Oncotelic Therapeutics Inc is the variable Liabilities, Current, reducing the Economic Capital Ratio by 146% points.

The company's Economic Capital Ratio, given in the ranking table, is 177%, being 98% points below the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	627
Cost of Goods Sold	0
Intangible Assets	21,884
Liabilities, Current	15,455
Liabilities, Non-Current	0
Other Assets	1,102
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	-1,391
Other Revenues	0
Property and Equipment	0
Research and Development	3,659
Selling, General and Administrative Expense	5,467

Output Variable	Value in 1000 USD
Assets	23,613
Liabilities	15,455
Expenses	9,126
Revenues	0
Stockholders Equity	8,158
Net Income	-10,517
Comprehensive Net Income	-10,517
BaseVar	24,793
ECR before LimitedLiability	37%
Economic Capital Ratio	177%